GlassScriptPhysician profile
Kevin Diasti
NPI 1376049304
$932.78
in general payments reported to CMS, 2019-2025
16 companies · $477 in 2025
The $477 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $456 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $139.90 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $130.04 | 2024 | Myrisk |
| Daiichi Sankyo INC. | $103.95 | 2024-2025 | Enhertu, Injectafer |
| Pfizer INC. | $96.67 | 2025 | |
| Genentech USA, INC. | $92.86 | 2024-2025 | Tecentriq, Alecensa, Tecentriq Hybreza |
| Bioprotect Medical, INC. | $85.42 | 2024 | Bioprotect Balloon Implant System |
| Eisai INC. | $47.50 | 2024-2025 | |
| Novocure INC. | $40.74 | 2024 | Optune, Optune Lua (Novottf-200t) |
| Astrazeneca Pharmaceuticals LP | $34.03 | 2025 | Enhertu |
| Janssen Biotech, INC. | $33.35 | 2025 | Talvey |
| Rigel Pharmaceuticals, INC. | $30.76 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Celgene Corporation | $24.81 | 2025 | Reblozyl |
| Lilly USA, LLC | $19.48 | 2025 | Jaypirca, Verzenio |
| Astellas Pharma US INC | $19.05 | 2025 | Vyloy |
| Acrotech Biopharma INC. | $17.74 | 2024 | Beleodaq |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $16.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Diasti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.